There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ardelyx (ARDX – Research Report), Generation Bio (GBIO – Research Report) and NextCure (NXTC – Research Report) with bullish sentiments.
Ardelyx (ARDX)
Piper Sandler analyst Christopher Raymond maintained a Buy rating on Ardelyx on January 19 and set a price target of $12.00. The company’s shares closed last Monday at $8.55, close to its 52-week high of $9.38.
According to TipRanks.com, Raymond is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ardelyx with a $12.25 average price target, which is a 46.7% upside from current levels. In a report issued on January 9, Citi also maintained a Buy rating on the stock with a $14.00 price target.
See the top stocks recommended by analysts >>
NextCure (NXTC)
Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on NextCure on January 19 and set a price target of $3.00. The company’s shares closed last Monday at $1.13, close to its 52-week low of $0.98.
According to TipRanks.com, Tenthoff is a 4-star analyst with an average return of
Currently, the analyst consensus on NextCure is a Strong Buy with an average price target of $4.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ARDX:
